{
  "pmcid": "PMC10880264",
  "pmid": "38377518",
  "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study",
  "overall_score": 0.622233696379309,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.8284387117937991,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8284387117937991,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Drug(s)": "escitalopram"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 38377518,
                "prediction": 38377518,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK",
                "score": 1.0,
                "match_status": "match"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": "intermediate metabolizer",
                "prediction": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9493458867073059,
                "match_status": "partial_match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "PD/PK terms": {
                "ground_truth": "dose-adjusted trough concentrations of",
                "prediction": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
                "score": 0.9461398720741272,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with",
                "score": 1.0,
                "match_status": "match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                "prediction": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
                "score": 0.9301581978797913,
                "match_status": "partial_match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "and",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": "normal metabolizer",
                "prediction": "rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9146915674209595,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8284387117937991,
            "annotation": {
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2C19",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Drug(s)": "escitalopram"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "intermediate",
                "prediction": "intermediate",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 38377518,
                "prediction": 38377518,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK",
                "score": 1.0,
                "match_status": "match"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": "intermediate metabolizer",
                "prediction": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9493458867073059,
                "match_status": "partial_match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "PD/PK terms": {
                "ground_truth": "dose-adjusted trough concentrations of",
                "prediction": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
                "score": 0.9461398720741272,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with",
                "score": 1.0,
                "match_status": "match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                "prediction": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
                "score": 0.9301581978797913,
                "match_status": "partial_match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "and",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": "normal metabolizer",
                "prediction": "rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9146915674209595,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8284387117937991,
            "annotation": {
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "PMID": 38377518,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-adjusted trough concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Drug(s)": "escitalopram"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "metabolizer",
                "prediction": "metabolizer",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 38377518,
                "prediction": 38377518,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK",
                "score": 1.0,
                "match_status": "match"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric",
                "score": 1.0,
                "match_status": "match"
              },
              "Metabolizer types": {
                "ground_truth": "intermediate metabolizer",
                "prediction": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9493458867073059,
                "match_status": "partial_match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "PD/PK terms": {
                "ground_truth": "dose-adjusted trough concentrations of",
                "prediction": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
                "score": 0.9461398720741272,
                "match_status": "partial_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with",
                "score": 1.0,
                "match_status": "match"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                "prediction": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
                "score": 0.9301581978797913,
                "match_status": "partial_match"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "and",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": "normal metabolizer",
                "prediction": "rapid metabolizer, ultrarapid metabolizer",
                "score": 0.9146915674209595,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 65,
        "items": [
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "normal",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rapid",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rapid",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "ultrarapid",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "Among 48 escitalopram-treated youth, CYP2C19 metabolizer phenotype significantly affected dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and elimination half-life t1/2 (p = 0.0008). Slower CYP2C19 metabolizers had greater AUC0\u201324, Ctrough, and t1/2 than faster metabolizers. Effect on dose-normalized Cmax trended but was not significant (p = 0.057).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Associated with increased dose-normalized AUC0\u201324, dose-normalized trough concentrations of, and elimination half-life of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to faster CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "dose-normalized AUC0\u201324, dose-normalized trough concentrations of, elimination half-life of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2C19 rapid metabolizer + CYP2C19 ultrarapid metabolizer",
              "Comparison Metabolizer types": "rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram (Fig. 1).",
                "Analysis of associations between CYP2C19 phenotype (including IM, NM, RM, and UM phenotypes) and pharmacokinetic parameters. CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram. AUC0\u201324, 24-hour area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.",
                "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "intermediate",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "normal",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rapid",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rapid",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "ultrarapid",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2C19",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or increases in TEASAP subscales (p = 0.39\u20130.92), though self-injury/suicidality/harm to others subscale showed only a nonsignificant trend (F = 2.32, df = 2, p = 0.09).",
              "Sentence": "CYP2C19 intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer phenotypes Are Not associated with adverse events related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2C19 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2C19 metabolizer phenotypes",
              "Comparison Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
                "Comparison of adverse events between an aggregate group of participants with normal or faster than normal CYP2C19 metabolism (NM, RM, or UM) compared to those with slower than normal metabolism (IM) similarly revealed no significant differences in rates of adverse events between aggregate CYP2C19 phenotypic groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19 intermediate metabolizer, CYP2C19 normal metabolizer, CYP2C19 rapid metabolizer, CYP2C19 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "poor",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "poor",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "intermediate",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "normal",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "ultrarapid",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "metabolism/PK",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters: AUC0\u201324 (p = 0.52), Cmax (p = 0.48), Ctrough (p = 0.56), or t1/2 (p = 0.50).",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with dose-normalized pharmacokinetic parameters of escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "dose-normalized pharmacokinetic parameters of",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
                "Consistent with prior studies (Bousman et al., [2023](#B7); Gram et al., [1993](#B21); Herrlin et al., [2003](#B22); Jeppesen et al., [1996](#B26); Sindrup et al., [1993](#B45)), we found that escitalopram pharmacokinetics were influenced by *CYP2C19* but not *CYP2D6.*",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "poor",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "poor",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "intermediate",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "normal",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "ultrarapid",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Slower CYP2D6 metabolizer phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale scores (p = 0.015). When grouped as slower (IM+PM) vs normal/faster (NM+UM), slower CYP2D6 metabolizers also had higher disinhibition and impulsivity scores (mean 3.0 vs 1.1, p = 0.02), and trends toward greater mania and akathisia-related scores (mania p = 0.07; akathisia/hyperkinesis/somatic anxiety p = 0.08).",
              "Sentence": "CYP2D6 poor and intermediate metabolizer phenotypes Are Associated with increased TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to CYP2D6 normal and ultrarapid metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP akathisia, hyperkinesis, and somatic anxiety scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 normal metabolizer + CYP2D6 ultrarapid metabolizer",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "There was also a trend for those with slower than normal 2D6 metabolism to have greater mania and greater akathisia, hyperkinesis, and somatic anxiety TEASAP subscale scores (mania: mean = 2.2 vs. 0.78, *p* = 0.07; akathisia, hyperkinesis, and somatic anxiety: mean = 1.8 vs. 0.60, *p* = 0.08)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "poor",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "poor",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "intermediate",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "intermediate",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "normal",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "normal",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "ultrarapid",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "ultrarapid",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizer",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "CYP2D6 phenotype was not significantly associated with hyperarousal events (p = 0.55), maximum PAERS score (p = 0.51), or other TEASAP subscales in the four-level ANOVA (p = 0.14\u20130.99), aside from the significant akathisia-related subscale association reported separately.",
              "Sentence": "CYP2D6 poor, intermediate, normal, and ultrarapid metabolizer phenotypes Are Not associated with overall escitalopram-related hyperarousal events and general adverse event severity in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to other CYP2D6 metabolizer phenotypes.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and maximum PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "other CYP2D6 metabolizer phenotypes",
              "Comparison Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
              "Citations": [
                "\u201cSlower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), **maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).**\u201d",
                "\u201cSlower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores. \u2026 **Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.**\u201d",
                "Table 2 (Analysis of Associations Between CYP Enzymes and Adverse Events) shows for **CYP2D6** phenotypes (PM, IM, NM, UM) that hyperarousal events (p = 0.55), max PAERS score (p = 0.51), and TEASAP subscales other than akathisia (p = 0.14\u20130.99) are not significantly different across poor, intermediate, normal, and ultrarapid metabolizer groups."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 poor metabolizer, CYP2D6 intermediate metabolizer, CYP2D6 normal metabolizer, CYP2D6 ultrarapid metabolizer",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs6311",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Participants with HTR2A \u22121438A allele (A/A or A/G genotypes) had greater increases in TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores than those with G/G (mean 1.7 \u00b1 2.8 vs 0.3 \u00b1 1.3, p = 0.017). No significant differences for other TEASAP subscales (p = 0.15\u20130.45), PAERS (p = 0.39), or hyperarousal events (p = 0.53).",
              "Sentence": "HTR2A rs6311 A/A and A/G genotypes Are Associated with increased TEASAP self-injury, suicidality, and harm to others subscale scores related to escitalopram in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to the G/G genotype.",
              "Alleles": "A/A + A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "TEASAP self-injury, suicidality, and harm to others subscale scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017). There was no significant difference between these genotype groups with respect to other TEASAP subscales (p = 0.15\u20130.45), PAERS score (p = 0.39), or the hyperarousal events (p = 0.53; Table 4).",
                "Participants with HTR2A \u22121438A (rs6311) allele (A/A or A/G genotypes) had greater increases in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to participants with G/G genotypes (mean = 1.7 \u00b1 2.8 vs. 0.3 \u00b1 1.3, p = 0.017).",
                "Adverse outcomes of interest were also influenced by HTR2A genotype, as we found greater increases in caregiver reports of high-risk behaviors (i.e., self-harm, suicidality, and harm to others) among those with HTR2A A/A and A/G genotypes."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs6311",
                "variant_id": "PA166154673",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs6311",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "HTR2A rs6311 A/A + A/G vs G/G showed no significant differences in other TEASAP subscales (mania, akathisia/hyperkinesis/somatic anxiety, disinhibition/impulsivity, irritability; p = 0.15\u20130.45), max PAERS score (p = 0.39), or hyperarousal events (p = 0.53).",
              "Sentence": "HTR2A rs6311 A/A and A/G genotypes Are Not associated with other escitalopram-related adverse event measures, including mania, akathisia, disinhibition, irritability, hyperarousal events, and overall PAERS scores, in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to the G/G genotype.",
              "Alleles": "A/A + A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "other TEASAP subscales and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "G/G",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017). We did not have a sufficient number of participants to further analyze differences between participants with *A/A* versus *A/G* genotypes. There was no significant difference between these genotype groups with respect to other TEASAP subscales (*p* = 0.15\u20130.45), PAERS score (*p* = 0.39), or the hyperarousal events (*p* = 0.53; [Table 4](#tb4)).\"",
                "\"There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72). There were no significant differences among *HTR2A* or *SLC6A4* genotypic groups with respect to gender or ancestry.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs6311",
                "variant_id": "PA166154673",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "SLC6A4",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "SLC6A4",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "L/L",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "L/L",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "SLC6A4",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "SLC6A4",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "L/S",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "L/S",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "SLC6A4",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "SLC6A4",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "S/S",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "S/S",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Comparisons of SLC6A4 S/S vs L/L + L/S genotypes showed no significant differences in TEASAP subscale increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
              "Sentence": "SLC6A4 S/S genotype Is Not associated with escitalopram-related hyperarousal events or other adverse event measures in children with depressive and/or anxiety symptoms and a familial risk for bipolar I disorder as compared to SLC6A4 L/L and L/S genotypes.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "hyperarousal events and TEASAP and PAERS adverse event scores related to",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:depressive symptoms, Disease:anxiety disorders, Disease:familial risk for bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cSLC6A4 genotype comparisons were based on homozygosity for the \u201cshort\u201d risk allele (S/S) versus homozygotes and carriers for the \u201clong\u201d allele (L/L and L/S), as rates of adverse events have tended to be highest among S/S genotyped groups in prior studies (Chang et al., 2017; Kato and Serretti, 2010; Park et al., 2015).\u201d",
                "\u201cThere was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).\u201d",
                "\u201cEscitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 L/L, SLC6A4 L/S, SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.738297409244946,
      "total_samples": 7,
      "ground_truth_annotations": {
        "count": 7,
        "matched_count": 6,
        "unmatched_count": 1,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.9672838866710662,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "rs6311",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "HTR2A",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "A/A",
                "score": 0.8702118992805481,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
                "score": 0.9740630388259888,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "HTR2A rs6311 G/G",
                "score": 0.828563928604126,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8467951476573944,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "CYP2D6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM",
                "score": 0.8472965359687805,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Akathisia, Side Effect:Hyperkinesis, Side Effect:Somatic anxiety, Side Effect:Disinhibition, Side Effect:Impulsivity",
                "score": 0.9301829934120178,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM/UM",
                "score": 0.8272367119789124,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8467009425163269,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "CYP2D6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "PM",
                "score": 0.8546534776687622,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Akathisia, Side Effect:Hyperkinesis, Side Effect:Somatic anxiety",
                "score": 0.9218840003013611,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM/UM",
                "score": 0.8272367119789124,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8467009425163269,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "PM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2D6",
                "score": 0.8632352352142334,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "PM",
                "score": 0.8546534776687622,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Akathisia, Side Effect:Hyperkinesis, Side Effect:Somatic anxiety",
                "score": 0.9218840003013611,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2D6 NM/UM",
                "score": 0.8272367119789124,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7426302433013916,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "CYP2C19",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2C19",
                "score": 0.8735596537590027,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "metabolism/PK",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM",
                "score": 0.8472965359687805,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "PK:Escitalopram AUC0\u201324, PK:Escitalopram trough concentration, PK:Escitalopram elimination half-life",
                "score": 0.8904250264167786,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2C19 NM/RM/UM",
                "score": 0.8150212168693542,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7426302433013916,
            "annotation": {
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "IM",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "CYP2C19",
                "score": 0.8735596537590027,
                "match_status": "partial_match"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "metabolism/PK",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "IM",
                "score": 0.8472965359687805,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "PK:Escitalopram AUC0\u201324, PK:Escitalopram trough concentration, PK:Escitalopram elimination half-life",
                "score": 0.8904250264167786,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CYP2C19 NM/RM/UM",
                "score": 0.8150212168693542,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452390301,
              "Variant/Haplotypes": "metabolizer",
              "Gene": "CYP2C19",
              "Drug(s)": "escitalopram",
              "PMID": 38377518,
              "Phenotype Category": "Toxicity",
              "Significance": "not stated",
              "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"Slower CYP2C19 metabolizers tended to have greater TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
              "Alleles": null,
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
              "Multiple phenotypes or diseases And/or": "or",
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "1452390301",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 8,
        "items": [
          {
            "variant": "IM",
            "gene": "CYP2D6",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "IM",
              "Gene": "CYP2D6",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Intermediate and other slower CYP2D6 phenotypes showed greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p=0.015) and higher disinhibition/impulsivity scores (mean 3.0 vs 1.1; p=0.02) compared with normal/faster phenotypes.",
              "Sentence": "CYP2D6 IM Is Associated with increased severity of Side Effect:Akathisia, Side Effect:Hyperkinesis, Side Effect:Somatic anxiety, Side Effect:Disinhibition, Side Effect:Impulsivity when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "IM",
              "Specialty Population": "Pediatric",
              "Metabolizer types": "intermediate metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Akathisia, Side Effect:Hyperkinesis, Side Effect:Somatic anxiety, Side Effect:Disinhibition, Side Effect:Impulsivity",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "CYP2D6 NM/UM",
              "Comparison Metabolizer types": "normal metabolizer, ultrarapid metabolizer",
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
                "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, *p* = 0.02).",
                "Our study suggests that the pharmacokinetics of escitalopram are influenced by CYP2C19 but not CYP2D6 phenotype. However, CYP2D6 phenotype and *HTR2A* genotype may influence the risk of adverse effects of escitalopram. Specifically, individuals with slower CYP2D6 phenotypes may be at increased risk of experiencing akathisia or worsening impulsivity."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6 IM",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HTR2A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Participants with HTR2A \u22121438G>A (rs6311) A/A or A/G genotypes had greater increases in TEASAP self-injury, suicidality, and harm to others subscale scores than G/G homozygotes (mean 1.7\u00b12.8 vs 0.3\u00b11.3; p=0.017).",
              "Sentence": "HTR2A rs6311 A/A Is Associated with increased severity of Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "HTR2A rs6311 G/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017). We did not have a sufficient number of participants to further analyze differences between participants with A/A versus A/G genotypes.",
                "Self-injury, suicidality and harm to others |   | 0.3 \u00b1 1.3 | 1.7 \u00b1 2.8 | 0.017* | 0.7 \u00b1 1.7 | 1.2 \u00b1 2.6 | 0.4"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HTR2A rs6311 A/A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "A/A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Participants with HTR2A \u22121438G>A (rs6311) A/A or A/G genotypes had greater increases in TEASAP self-injury, suicidality, and harm to others subscale scores than G/G homozygotes (mean 1.7\u00b12.8 vs 0.3\u00b11.3; p=0.017).",
              "Sentence": "HTR2A rs6311 A/A Is Associated with increased severity of Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "A/A",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "HTR2A rs6311 G/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017). We did not have a sufficient number of participants to further analyze differences between participants with A/A versus A/G genotypes.",
                "Self-injury, suicidality and harm to others |   | 0.3 \u00b1 1.3 | 1.7 \u00b1 2.8 | 0.017* | 0.7 \u00b1 1.7 | 1.2 \u00b1 2.6 | 0.4"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HTR2A rs6311 A/A",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "HTR2A",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "HTR2A",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A \u22121438G>A (rs6311) A/G heterozygotes, grouped with A/A, showed increased TEASAP self-injury, suicidality, and harm to others scores compared with G/G homozygotes (p=0.017).",
              "Sentence": "HTR2A rs6311 A/G Is Associated with increased severity of Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "HTR2A rs6311 G/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001). CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter. Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores. HTR2A A/A and A/G genotypes were associated with increased TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (p = 0.017). Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
                "Adverse outcomes of interest were also influenced by HTR2A genotype, as we found greater increases in caregiver reports of high-risk behaviors (i.e., self-harm, suicidality, and harm to others) among those with HTR2A A/A and A/G genotypes."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HTR2A rs6311 A/G",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs6311",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "rs6311",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A \u22121438G>A (rs6311) A/G heterozygotes, grouped with A/A, showed increased TEASAP self-injury, suicidality, and harm to others scores compared with G/G homozygotes (p=0.017).",
              "Sentence": "HTR2A rs6311 A/G Is Associated with increased severity of Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "HTR2A rs6311 G/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001). CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter. Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores. HTR2A A/A and A/G genotypes were associated with increased TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (p = 0.017). Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
                "Adverse outcomes of interest were also influenced by HTR2A genotype, as we found greater increases in caregiver reports of high-risk behaviors (i.e., self-harm, suicidality, and harm to others) among those with HTR2A A/A and A/G genotypes."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HTR2A rs6311 A/G",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "A/G",
            "gene": "HTR2A",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "A/G",
              "Gene": "HTR2A",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "HTR2A \u22121438G>A (rs6311) A/G heterozygotes, grouped with A/A, showed increased TEASAP self-injury, suicidality, and harm to others scores compared with G/G homozygotes (p=0.017).",
              "Sentence": "HTR2A rs6311 A/G Is Associated with increased severity of Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "A/G",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "severity of",
              "Phenotype": "Side Effect:Self-injury, Side Effect:Suicidality, Side Effect:Harm to others",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "HTR2A rs6311 G/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001). CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter. Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores. HTR2A A/A and A/G genotypes were associated with increased TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (p = 0.017). Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events.",
                "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
                "Adverse outcomes of interest were also influenced by HTR2A genotype, as we found greater increases in caregiver reports of high-risk behaviors (i.e., self-harm, suicidality, and harm to others) among those with HTR2A A/A and A/G genotypes."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "HTR2A rs6311 A/G",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "SLC6A4",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "SLC6A4",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No significant differences in TEASAP subscale increases, max PAERS score, or hyperarousal frequency were observed between SLC6A4 S/S and L/L+L/S genotype groups (p=0.40\u20130.81 for TEASAP; p=0.72 for PAERS; p=0.72 for hyperarousal).",
              "Sentence": "SLC6A4 S/S Is Not associated with Side Effect:Hyperarousal, Side Effect:General adverse events when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Hyperarousal, Side Effect:General adverse events",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "SLC6A4 L/L+L/S",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "6",
              "Citations": [
                "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
                "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72). There were no significant differences among *HTR2A* or *SLC6A4* genotypic groups with respect to gender or ancestry."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "S/S",
            "gene": "SLC6A4",
            "drug": "escitalopram",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "S/S",
              "Gene": "SLC6A4",
              "Drug(s)": "escitalopram",
              "PMID": "38377518",
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "No significant differences in TEASAP subscale increases, max PAERS score, or hyperarousal frequency were observed between SLC6A4 S/S and L/L+L/S genotype groups (p=0.40\u20130.81 for TEASAP; p=0.72 for PAERS; p=0.72 for hyperarousal).",
              "Sentence": "SLC6A4 S/S Is Not associated with Side Effect:Hyperarousal, Side Effect:General adverse events when treated with escitalopram in children with Disease:Depression and/or Disease:Anxiety and Disease:Family history of bipolar I disorder.",
              "Alleles": "S/S",
              "Specialty Population": "Pediatric",
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": null,
              "Phenotype": "Side Effect:Hyperarousal, Side Effect:General adverse events",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in children with",
              "Population Phenotypes or diseases": "Disease:Depression and/or Disease:Anxiety, Disease:Family history of bipolar I disorder",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "SLC6A4 L/L+L/S",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38377518",
              "Variant Annotation ID_norm": "6",
              "Citations": [
                "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
                "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72). There were no significant differences among *HTR2A* or *SLC6A4* genotypic groups with respect to gender or ancestry."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "SLC6A4 S/S",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "escitalopram",
                "drug_id": "PA10074",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7610643003384272,
      "total_samples": 4,
      "ground_truth_annotations": {
        "count": 4,
        "matched_count": 4,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7022046762354234,
            "annotation": {
              "Study Parameters ID": 1452390309,
              "Variant Annotation ID": 1452390301,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.09",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390309,
                "prediction": 3,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390301,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and TEASAP self-injury, suicidality and harm to others subscale change",
                "score": 0.9374794960021973,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.09",
                "prediction": "= 0.09",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7021712099804598,
            "annotation": {
              "Study Parameters ID": 1452390361,
              "Variant Annotation ID": 1452390352,
              "Study Type": null,
              "Study Cases": 66.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.017",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390361,
                "prediction": 17,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390352,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and TEASAP self-injury, suicidality and harm to others subscale change",
                "score": 0.9369105696678162,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.017",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.667517845770892,
            "annotation": {
              "Study Parameters ID": 1452390397,
              "Variant Annotation ID": 1452390389,
              "Study Type": null,
              "Study Cases": 64.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.017",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390397,
                "prediction": 26,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390389,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 64.0,
                "prediction": 66,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
                "prediction": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and TEASAP akathisia, hyperkinesis and somatic anxiety subscale change",
                "score": 0.9478033781051636,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.81",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.614215563325321,
            "annotation": {
              "Study Parameters ID": 1452390351,
              "Variant Annotation ID": 1452390346,
              "Study Type": null,
              "Study Cases": 48.0,
              "Study Controls": null,
              "Characteristics": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.025",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452390351,
                "prediction": 1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390346,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 48.0,
                "prediction": 66,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12-17 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0-24",
                "prediction": "Escitalopram-treated depressed and/or anxious youth (12\u201317 years) at familial risk for bipolar I disorder, comparison of CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes for hyperarousal events",
                "score": 0.9416645765304565,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.025",
                "prediction": "= 0.29",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6",
                "prediction": "Multiple Groups",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 24,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 2,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated depressed and/or anxious youth at familial risk for bipolar I disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and maximum PAERS (Pediatric Adverse Events Rating Scale) score",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.90",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and TEASAP mania subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.39",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and TEASAP akathisia, hyperkinesis and somatic anxiety subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.41",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and TEASAP disinhibition and impulsivity subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.84",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2C19 intermediate, normal, rapid+ultrarapid metabolizer phenotypes and TEASAP irritability subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.73",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated depressed and/or anxious youth at familial risk for bipolar I disorder, comparison of CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes for hyperarousal events",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.55",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and maximum PAERS score",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.51",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 10,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and TEASAP self-injury, suicidality and harm to others subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.74",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 11,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and TEASAP mania subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.28",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 12,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and TEASAP akathisia, hyperkinesis and somatic anxiety subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.015",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 13,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and TEASAP disinhibition and impulsivity subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.14",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 14,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between CYP2D6 poor, intermediate, normal, ultrarapid metabolizer phenotypes and TEASAP irritability subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.99",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 15,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated depressed and/or anxious youth at familial risk for bipolar I disorder, comparison of HTR2A G/G versus A/A+A/G genotypes for hyperarousal events",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.53",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 16,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and maximum PAERS score",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.39",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 18,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and TEASAP mania subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.45",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 19,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and TEASAP akathisia, hyperkinesis and somatic anxiety subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.15",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 20,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and TEASAP disinhibition and impulsivity subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.41",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 21,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between HTR2A G/G versus A/A+A/G genotypes and TEASAP irritability subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.26",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 22,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated depressed and/or anxious youth at familial risk for bipolar I disorder, comparison of SLC6A4 S/S versus L/L+L/S genotypes for hyperarousal events",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.72",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 23,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and maximum PAERS score",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.72",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 24,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and TEASAP self-injury, suicidality and harm to others subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.40",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 25,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and TEASAP mania subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.65",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 27,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and TEASAP disinhibition and impulsivity subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.41",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 28,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 66,
              "Study Controls": null,
              "Characteristics": "Escitalopram-treated youth at familial risk for bipolar disorder, association between SLC6A4 S/S versus L/L+L/S genotypes and TEASAP irritability subscale change",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.60",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}